US cos apply imaging to nasal spray development

By Phil Taylor

- Last updated on GMT

Related tags Generic drug

Two US firms have joined forces to develop what they hope will be a faster and more accurate method of sizing drug particles in nasal sprays.

The first company, ChemImage, has developed an imaging system known as Falcon II which can be used to obtain detailed chemical images of material morphology, composition, structure, size and concentration in nasal sprays.

The second, Next Breath, is a CRO specialising in in vitro​ bioequivalence testing for nasal sprays and chemistry, manufacturing and controls (CMC) testing for inhalation and nasal spray products.

Falcon II can be used to distinguish active pharmaceutical ingredients in formulated products and discriminate between particles of API and those of an excipient or a surfactant. It can count and measure API particles, and confirm particle identity using Raman spectroscopy, according to ChemImage.

ChemImage has been actively promoting use of the Falcon II to CROs and pharmaceutical companies, either through purchase of the technology or outsourcing to its in-house lab services, so a formal alliance with Next Breath represents a logical next step.

Among Next Breath’s near-term goals is to find a faster and reproducible method for drug-particle sizing relative to bioequivalence studies, to help generics companies bring nasal spray products faster.

The companies are working on validation testing of the Falcon II system in bioequivalence testing of nasal spray products and expects to complete the work in 2010.

Ryan Priore, Senior Scientist, ChemImage, said: "Pharmaceutical companies, particularly generic drug manufacturers focused on nasal spray suspensions, are looking to improve their time-to-market through the use of better imaging technology/​”

“The potential payoff is a faster, more accurate and safe way to bring the drug to market.​"

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more